A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED
Sponsor: Pfizer
A PHASE2 clinical study on COVID-19, this trial is completed. The trial is conducted by Pfizer and has accumulated 19 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 14 earlier versions
-
Dec 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .